Skip to main content
. 2019 Dec 27;13(2):365–371. doi: 10.1016/j.tranon.2019.11.006

Table 1.

Scoring of B7–H3 immunostaining intensity across tumor types

Tumor type Positivity Staining Intensity
Low Medium High
ATRT 13/13 (100%) 0/13 (0%) 1/13 (8%) 12/13 (92%)
Ependymoma 24/24 (100%) 0/24 (0%) 9/24 (38%) 15/24 (62%)
Medulloblastoma 33/33 (100%) 1/33 (3%) 15/33 (45%) 17/33 (52%)
CNS embryonal tumor 5/5 (100%) 0/5 (0%) 2/5 (40%) 3/5 (60%)
CPT 11/11 (100%) 2/11 (18%) 7/11 (64%) 2/11 (18%)
Meningioma 16/16 (100%) 1/16 (6%) 4/16 (25%) 11/16 (69%)
Craniopharyngioma 13/13 (100%) 1/13 (8%) 2/13 (15%) 10/13 (77%)
Neuronal/glial mixed 28/28 (100%) 17/28 (61%) 6/28(21%) 5/28 (18%)
Glioma 69/80 (86%) 26/80 (33%) 30/80 (37%) 13/80 (16%)

  • •Pilocytic astrocytoma, grade I

 20/27 (74%) 13/27 (48%) 6/27 (22%) 1/27 (4%)

  • •Pilomyxoid/pilocytic astrocytoma, grade II

 2/2 (100%) 2/2 (100%) 0/2 (0%) 0/2 (0%)

  • •Fibrillary/diffuse astrocytoma, grade II

 7/8 (88%) 4/8 (50%) 3/8 (38%) 0/8 (0%)

  • •Oligodendrogliomas, grade II

 5/5 (100%) 2/5 (40%) 2/5 (40%) 1/5 (20%)

  • •Anaplastic astrocytoma, grade III

 0/2 (100%) 0/2 (100%) 0/2 (100%) 0/2 (100%)

  • •Glioblastoma, grade IV

 15/15 (100%) 2/15 (13%) 5/15 (33%) 8/15 (53%)

  • •DIPG

 20/21 (95%) 3/21 (14%) 14/21 (67%) 3/21 (14%)

CNS, central nervous system; CPT, choroid plexus tumor; DIPG, diffuse intrinsic pontine glioma.